BCL-XL is crucial for progression through the adenoma-to-carcinoma sequence of colorectal cancer
Open Access
- 11 June 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cell Death & Differentiation
- Vol. 28 (12), 3282-3296
- https://doi.org/10.1038/s41418-021-00816-w
Abstract
Evasion of apoptosis is a hallmark of cancer, which is frequently mediated by upregulation of the antiapoptotic BCL-2 family proteins. In colorectal cancer (CRC), previous work has highlighted differential antiapoptotic protein dependencies determined by the stage of the disease. While intestinal stem cells (ISCs) require BCL-2 for adenoma outgrowth and survival during transformation, ISC-specific MCL1 deletion results in disturbed intestinal homeostasis, eventually contributing to tumorigenesis. Colon cancer stem cells (CSCs), however, no longer require BCL-2 and depend mainly on BCL-XL for their survival. We therefore hypothesized that a shift in antiapoptotic protein reliance occurs in ISCs as the disease progresses from normal to adenoma to carcinoma. By targeting antiapoptotic proteins with specific BH3 mimetics in organoid models of CRC progression, we found that BCL-2 is essential only during ISC transformation while MCL1 inhibition did not affect adenoma outgrowth. BCL-XL, on the other hand, was crucial for stem cell survival throughout the adenoma-to-carcinoma sequence. Furthermore, we identified that the limited window of BCL-2 reliance is a result of its downregulation by miR-17-5p, a microRNA that is upregulated upon APC-mutation driven transformation. Here we show that BCL-XL inhibition effectively impairs adenoma outgrowth in vivo and enhances the efficacy of chemotherapy. In line with this dependency, expression of BCL-XL, but not BCL-2 or MCL1, directly correlated to the outcome of chemotherapy-treated CRC patients. Our results provide insights to enable the rational use of BH3 mimetics in CRC management, particularly underlining the therapeutic potential of BCL-XL targeting mimetics in both early and late-stage disease.Keywords
This publication has 64 references indexed in Scilit:
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing plateletsNature Medicine, 2013
- miRmap: Comprehensive prediction of microRNA target repression strengthNucleic Acids Research, 2012
- Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic ChemotherapyScience, 2011
- The landscape of somatic copy-number alteration across human cancersNature, 2010
- Distinct Thresholds Govern Myc's Biological Output In VivoCancer Cell, 2008
- Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimeticJCI Insight, 2008
- Identification of stem cells in small intestine and colon by marker gene Lgr5Nature, 2007
- Augmentation of tumor angiogenesis by a Myc-activated microRNA clusterNature Genetics, 2006
- c-Myc-regulated microRNAs modulate E2F1 expressionNature, 2005
- The Hallmarks of CancerCell, 2000